IP Verse

Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis

PatentPatent Analysis

EP3351246

NOVARTIS
Application Number
EP18155644A
Filing Date
Feb 18, 2002
Status
Revoked
Oct 23, 2023
Grant Date
Sep 18, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Biblio Summary

The patent EP3351246B8 was granted to Novartis on Sep 18, 2019 following the initial filing on Feb 18, 2002 under the application number EP18155644A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROW GENERIQUESFeb 24, 2020ADMISSIBLE
TEVA PHARMACEUTICALSFeb 22, 2020ADMISSIBLE
GENERICS UKFeb 21, 2020ADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELJan 29, 2020ADMISSIBLE
ZENTIVA PHARMASep 16, 2019ADMISSIBLE
ACCORD HEALTHCAREJul 31, 2019WITHDRAWN
ETHYPHARMJul 3, 2019ADMISSIBLE
BIOGARANJul 1, 2019ADMISSIBLE
STADA ARZNEIMITTELMay 23, 2019ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents